Janux is a clinical-stage company developing precision-engineered immunotherapies that have the potential to generate potent and durable immune responses without causing systemic safety issues. Janux is using its TRACTr, TRACIr and ARM platforms to engineer novel drug candidates that are designed to overcome the traditional limitations associated with contemporary immunotherapies.